Predictive effects of serum levels of GDF11 and Copeptin in the therapeutic effects and death risk of congestive heart failure patients treatment with Nesiritide

CUI Jiangman; SHEN Xun; WANG Jiao; SUN Yunjing; ZHOU Song; CUI Zhenchuan

doi:10.13898/j.cnki.issn.1000-2200.2024.01.014

Journal of Bengbu Medical University > 2024 > 49(1): 63-67. > DOI: 10.13898/j.cnki.issn.1000-2200.2024.01.014

CUI Jiangman, SHEN Xun, WANG Jiao, SUN Yunjing, ZHOU Song, CUI Zhenchuan. Predictive effects of serum levels of GDF11 and Copeptin in the therapeutic effects and death risk of congestive heart failure patients treatment with Nesiritide[J]. Journal of Bengbu Medical University, 2024, 49(1): 63-67. DOI: 10.13898/j.cnki.issn.1000-2200.2024.01.014

Citation:

PDF (1120 KB)

Predictive effects of serum levels of GDF11 and Copeptin in the therapeutic effects and death risk of congestive heart failure patients treatment with Nesiritide

Department of Cardiology, The Third Hospital of Xingtai, Xingtai Hebei 054000, China

More Information

Received Date: May 29, 2022
Revised Date: May 29, 2023

Graphical Abstract

Abstract

Abstract

ObjectiveTo investigaste the predictive effects of serum levels of growth differentiation factor 11 (GDF11) and Copeptin in the therapeutic effects and death risk of congestive heart failure(CHF) patients treated with Nesiritide.
MethodsA total of 156 CHF patients were selected, and treated with Nesiritide.The NYHA cardiac function grade, ECG QRS width, left ventricular end-diastolic diameter(LVEDD), left ventricular ejection fraction(LVEF) and serum levels of GDF11 and Copeptin were compared before and after treatment.The patients were followed up to October 2021, and divided into the survival group and death group according to their prognosis.The univariate and multivariate logistic regression analysis were used to analyze the baseline data of two groups, and the receiver operating characteristic curve(ROC) was used to analyze the value of serum GDF11 and Copeptin in predicting the risk of death.
ResultsIn NYHA cardiac function classification before treatment, 48 cases were grade Ⅱ, 36 cases were grade Ⅲ and 72 cases were grade Ⅳ.In NYHA cardiac function grading after treatment, 29 cases were grade Ⅰ, 67 cases were grade Ⅱ, 43 cases were grade Ⅲ and 17 cases were grade Ⅳ, the cardiac function were significantly improved(P < 0.01).After treatment, the QRS width and LVEDD values were significantly lower than those before treatment(P < 0.01), the LVEF values were significantly higher than those before treatment(P < 0.01), and the GDF11 and Copeptin values were significantly lower than those before treatment (P < 0.01).The results of Pearson correlation analysis showed that the serum levels of GDF11 and Copeptin were positively correlated with LVEDD(r=0.291 and 0.268) and QRS width(r=0.247 and 0.222) (P < 0.01), and negative correlation with LVEF(r=-0.310 and -0.261) (P < 0.01).The patients were followed up to October 2021, and the median follow-up time was (29.23±3.00) months.The indexes of hs-CRP, TNF-α, GDF11 and Copeptin in the death group were higher than those in survival group(P < 0.01).The results of logistic regression analysis showed that the serum levels of GDF11 (OR=1.702, 95%CI: 1.348-2.150) and serum Copeptin(OR=2.166, 95%CI: 1.458-3.219) were the influencing factors of the death of CHF patients(P < 0.01).According to the ROC curve, the critical value of serum GDF11 diagnosis was 765.44 ng/mL, the corresponding sensitivity, specificity and AUC were 70.37%, 70.16%, and 0.785(95%CI: 0.730-0.839), respectively.The critical value of serum Copeptin diagnosis was 26.29 pmol/L, the corresponding sensitivity, specificity and AUC were 59.26%, 59.68% and 0.635(95%CI: 0.571-0.700), respectively.The sensitivity, specificity and AUC of the combined diagnosis were 88.89%, 78.23% and 0.878(95%CI: 0.831-0.908), resdpectively, which were significantly higher than those of GDF11 and Copeptin alone(P < 0.05).
ConclusionsThe treatment of CHF with Nesiritide is effective, which can effectively improve the cardiac function, and reduce the serum levels of GDF11 and Copeptin.The serum GDF11 and Copeptin are the independent influencing factors of CHF death, and which can improve the diagnostic efficiency of predicting death in CHF patients through combined diagnosis.
- congestive heart failure,
- Nesiritide,
- growth differentiation factor 11,
- Copeptin

FullText(HTML)

References (19)

References

[1]	王亚旭, 孙林, 姜雪梅, 等. 心脉隆注射液治疗慢性心力衰竭病人的疗效及近期预后的临床研究[J]. 蚌埠医学院学报, 2021, 46(7): 862. doi: 10.13898/j.cnki.issn.1000-2200.2021.07.006
[2]	CHEN J, ARONOWITZ P. Congestive heart failure[J]. Med Clin North Am, 2022, 106(3): 447. doi: 10.1016/j.mcna.2021.12.002
[3]	GUO L, GUO X, CHANG Y, et al. Prevalence and risk factors of heart failure with preserved ejection fraction: a population-based study in Northeast China[J]. Int J Environ Res Public Health, 2016, 13(8): 770. doi: 10.3390/ijerph13080770
[4]	SIONIS A, SIONIS GREEN A, MANITO LORITE N, et al. Comments on the 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Rev Esp Cardiol (Engl Ed), 2016, 69(12): 1119. doi: 10.1016/j.recesp.2016.09.056
[5]	ZHAO X, ZHANG DQ, SONG R, et al. Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis[J]. J Int Med Res, 2020, 48(1): 300060519897194.
[6]	ZHANG C, LIN Y, LIU Q, et al. Growth differentiation factor 11 promotes differentiation of MSCs into endothelial-like cells for angiogenesis[J]. J Cell Mol Med, 2020, 24(15): 8703. doi: 10.1111/jcmm.15502
[7]	CHRIST-CRAIN M, FENSKE WK. Copeptin in the differential diagnosis of hypotonic polyuria[J]. J Endocrinol Invest, 2020, 43(1): 21. doi: 10.1007/s40618-019-01087-6
[8]	BALLING L, GOETZE JP, JUNG MH, et al. Copeptin levels and invasive hemodynamics in patients with advanced heart failure[J]. Biomark Med, 2018, 12(8): 861. doi: 10.2217/bmm-2017-0439
[9]	中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 30. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYW201910003.htm
[10]	GIUSTINO G, LINDENFELD J, ABRAHAM WT, et al. NYHA functional classification and outcomes after transcatheter mitral valve repair in heart failure: The COAPT Trial[J]. JACC Cardiovasc Interv, 2020, 13(20): 2317. doi: 10.1016/j.jcin.2020.06.058
[11]	SINNENBERG L, GIVETZ MM. Acute heart failure[J]. Trends Cardiovasc Med, 2020, 30(2): 104. doi: 10.1016/j.tcm.2019.03.007
[12]	WARREN JD, AITKEN-PALMER C, WELDON AD, et al. Congestive heart failure associated with pregnancy in okapi (OKAPIA JOHNSTONI)[J]. J Zoo Wildl Med, 2017, 48(1): 179. doi: 10.1638/2016-0090.1
[13]	王丹. 冠心病PCI术患者HMGB1、BNP水平变化及与发生心力衰竭的关系[J]. 河北医药, 2019, 41(2): 199. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ201902009.htm
[14]	彭龙希, 李正翔. 脑钠肽相关药物在心力衰竭治疗中的研究进展[J]. 药学与临床研究, 2019, 27(1): 61. https://www.cnki.com.cn/Article/CJFDTOTAL-YXLY201901016.htm
[15]	缪世锋, 钱炜春. 新活素对老年急性心肌梗死伴心力衰竭后心脏纤维化的影响及预后分析[J]. 实用老年医学, 2021, 35(8): 852. doi: 10.3969/j.issn.1003-9198.2021.08.016
[16]	YUAN X, BHAT OM, LOHNER H, et al. Inhibitory effects of growth differentiation factor 11 on autophagy deficiency-induced dedifferentiation of arterial smooth muscle cells[J]. Am J Physiol Heart Circ Physiol, 2019, 316(2): H345. doi: 10.1152/ajpheart.00342.2018
[17]	LU L, BAI X, CAO Y, et al. Growth differentiation factor 11 promotes neurovascular recovery after stroke in mice[J]. Front Cell Neurosci, 2018, 12: 205.
[18]	SKVORTSOV AA, NARUSOV OY, MUKSINOVA MD, et al. Clinical significance of serial biomarkers activity determination after acute heart failure decompensation: sST2 NT-proBNP role during long-term follow-up[J]. Kardiologiia, 2018, 58(12S): 27. doi: 10.18087/cardio.2634
[19]	LATYPOVA GM, BYCHENKOVA MA, KATAYEV VA, et al. Composition and cardioprotective effects of Primula veris L. solid herbal extract in experimental chronic heart failure[J]. Phytomedicin, 2019, 54: 17. doi: 10.1016/j.phymed.2018.09.015

Cited By

Get Citation

PDF

XML

Article views (115) PDF downloads (6)

Turn off MathJax

Article Contents

Abstract

References

Predictive effects of serum levels of GDF11 and Copeptin in the therapeutic effects and death risk of congestive heart failure patients treatment with Nesiritide

Abstract

References

Catalog

Export File

Citation

Format

Content